General Catalyst led the financing alongside a syndicate of new and existing investors to support the developer of antibody-based therapeutics.
"KnotBodies represent a potential breakthrough biologic drug modality, delivering greater potency, selectivity, and durability. We believe they will provide transformational new therapeutic options for ion channel- and GPCR-driven diseases across a wide range of therapeutic areas with a remaining high unmet medical need. The calibre of our international investor syndicate validates our approach, and I would like to welcome our new investors to Maxion and thank our existing investors for their continued support."
The investment was led by 20VC with participation from prominent angel and strategic investors.
"We’ve tried hundreds of tools, very few actually work. Fyxer AI is different. Our team loves it, and more importantly, it gives us an edge. We can now respond faster than our competition, and in Real Estate, the fastest to respond wins. It’s that simple."
The oversubscribed round was led by Bethnal Green Ventures with participation from a group of specialist investors and angels.
"Vouchsafe was one of the standout successes of the CivTech programme, tackling a challenge that affects millions. Their approach to identity verification is a game-changer, making it easier, faster, and more cost-effective for public services to reach those who need them most. This funding is a testament to the impact they are already making, and I’m excited to see how they scale their work to help even more people access vital services."
The pre-seed round was backed by participants including Y Combinator and the UK government.
"The discovery of novel pharmaceuticals is one of our most important weapons in fighting disease. However, the drug development pipeline is often driven by trial-and-error and held up for many months during the identification of scalable manufacturing processes, delaying clinical trials. Our AI-powered models learn from historical data, cutting up to 95% of experimental work and accelerating these workflows by 30x."
The funding round was backed by the Midlands Engine Investment Fund, Mercia Ventures, and Pioneer Group.
"Our mission is to help companies avoid unnecessary animal testing and provide more accurate and relevant test results. This latest funding will enable us to continue building our range of tests and assays and use our model for different purposes, across different industries. We will also continue engaging with regulators to adapt industry standards tests to become animal free, and establish ImmuONE as a leading provider."
